Biogen

HaemaLogiX Announces Appointment of Damian Clarke-Bruce as Managing Director and CEO

Retrieved on: 
Tuesday, November 14, 2023
Carmine, UNSW, MIT, University of Sydney, MGSM, Marketing, Neuroscience, Therapy, Novartis, Immunotherapy, Knowledge, Harvard University, Pharmaceutical industry, Management, Master of Science, Biogen

SYDNEY, Nov. 14, 2023 /PRNewswire/ -- HaemaLogiX Ltd, a clinical stage Australian biotech, is pleased to announce the appointment of Damian Clarke-Bruce as Managing Director and CEO, effective 13 November 2023.

Key Points: 
  • SYDNEY, Nov. 14, 2023 /PRNewswire/ -- HaemaLogiX Ltd, a clinical stage Australian biotech, is pleased to announce the appointment of Damian Clarke-Bruce as Managing Director and CEO, effective 13 November 2023.
  • "I congratulate Damian on his appointment, and I look forward to working together to further build toward the successful commercialisation of the company and our products."
  • Mr Clarke-Bruce most recently held the position of Managing Director and CEO for Race Oncology.
  • HaemaLogiX Director Alan Liddle said: "It's a pleasure to welcome Damian to the HaemaLogiX leadership team.

HaemaLogiX Announces Appointment of Damian Clarke-Bruce as Managing Director and CEO

Retrieved on: 
Tuesday, November 14, 2023
Carmine, UNSW, MIT, University of Sydney, MGSM, Marketing, Neuroscience, Therapy, Novartis, Immunotherapy, Knowledge, Harvard University, Pharmaceutical industry, Management, Master of Science, Biogen

SYDNEY, Nov. 13, 2023 /PRNewswire/ -- HaemaLogiX Ltd, a clinical stage Australian biotech, is pleased to announce the appointment of Damian Clarke-Bruce as Managing Director and CEO, effective 13 November 2023.

Key Points: 
  • SYDNEY, Nov. 13, 2023 /PRNewswire/ -- HaemaLogiX Ltd, a clinical stage Australian biotech, is pleased to announce the appointment of Damian Clarke-Bruce as Managing Director and CEO, effective 13 November 2023.
  • "I congratulate Damian on his appointment, and I look forward to working together to further build toward the successful commercialisation of the company and our products."
  • Mr Clarke-Bruce most recently held the position of Managing Director and CEO for Race Oncology.
  • HaemaLogiX Director Alan Liddle said: "It's a pleasure to welcome Damian to the HaemaLogiX leadership team.

Nereid Therapeutics Appoints Michael Kauffman as CEO

Retrieved on: 
Monday, November 13, 2023
Epix Pharmaceuticals, Research, Organization, Johns Hopkins, Therapy, Onyx Pharmaceuticals, MGM+, Biotechnology, Hospital, Verastem Oncology, EMA, Patient, Doctor of Philosophy, Takeda Oncology, Conference, Harvard Medical School, Drug discovery, Cancer, CMO, ATP, Beth Israel Hospital, Massachusetts General Hospital, Coronavirus Scientific Advisory Board, Amgen, Pharmaceutical industry, Nereids, Biogen

BOSTON, Nov. 13, 2023 /PRNewswire/ -- Nereid Therapeutics, a biotechnology company that is discovering new disease treatments by applying pioneering research and technologies to biomolecular condensates, announced today that Michael Kauffman, M.D., Ph.D., has joined the company as President and Chief Executive Officer. Dr. Kauffman will also join the Nereid Board of Directors. Spiros Liras, Ph.D., a venture partner at Apple Tree Partners (ATP) who has been acting CEO of Nereid since the company was created by ATP in late 2020, will continue to serve on Nereid's Board of Directors and the company's Scientific Advisory Board.

Key Points: 
  • Dr. Kauffman will also join the Nereid Board of Directors.
  • "Michael brings to Nereid the right energy at the right time.
  • He currently chairs the boards of BiVictriX Therapeutics and Incendia Therapeutics and serves on the Boards of Verastem Oncology, Kezar Life Sciences, and Adicet Bio.
  • Dr. Kauffman and other members of the Nereid leadership team will be onsite for meetings at the 42nd Annual J.P. Morgan Healthcare Conference taking place January 8-11, 2024, in San Francisco, CA.

eClinical Solutions Advances Modern Digital Trials at Engage 2023 Conference

Retrieved on: 
Thursday, November 9, 2023
Technology, Biotechnology, Health, Pharmaceutical, Professional Services, Artificial Intelligence, Practice Management, Research, Software, Data Analytics, Health Technology, Science, Data Management, Clinical Trials, Cloud, Drug development, Digital, SCE, Intelligence, Biogen, BioNTech, PwC, The Newbury Boston, Snowflake, IDC, Organization, Biometrics, Multimedia, Tufts University School of Medicine, Clinical data management, BioMarin Pharmaceutical, Medicine, Tufts Center for the Study of Drug Development, AI, Patient, Disruptive innovation, Automation

eClinical Solutions , a global provider of digital clinical software and services, will bring together prominent clinical development leaders on Thursday, November 16 and Friday, November 17 for its fifth annual client and partner conference, Engage 2023.

Key Points: 
  • eClinical Solutions , a global provider of digital clinical software and services, will bring together prominent clinical development leaders on Thursday, November 16 and Friday, November 17 for its fifth annual client and partner conference, Engage 2023.
  • Taking place at The Newbury Boston, Engage 2023 includes nearly 280 attendees representing 60 life science organizations, and features five corporate sponsors including Halloran Consulting, PwC, Flatiron, LumaBridge, and Snowflake.
  • He will share recommendations for advancing healthcare and life science digital transformation and innovation, including the AI-embedded components of a modern end-to-end digital data blueprint that delivers and demonstrates analytics value at scale.
  • For more information about Engage and to see the agenda, please visit: www.eclinicalsol.com/event/elluminate-engage/ .

TREEFROG THERAPEUTICS REINFORCES EXECUTIVE COMMITTEE WITH THREE NEW MEMBERS

Retrieved on: 
Thursday, November 9, 2023
University of Los Andes (Colombia), IPO, Biogen, Therapy, Tajikistan State University of Law, Business, & Politics, Tree, Doctor of Philosophy, MBA, Engineering, HEC Paris, Central Executive Committee (PAP), Politics, Growth, Trinity College, Medicine, Paris, Executive Committee, Business, Senior, University of Hamburg, Ethicon, University, Trinity College Dublin, Sanofi, International communication, La Jolla Institute for Immunology, Immunology, Management, Bayer, Merck

BORDEAUX, France, Nov. 9, 2023 /PRNewswire/ -- TreeFrog Therapeutics, a global biotechnology company advancing a pipeline of cell therapies based on a disruptive proprietary technology platform, today announced the appointment of three new members to the Executive Team.

Key Points: 
  • "Since our inception in 2018, TreeFrog has made great strides, and I am proud of the progress the teams have made in our therapeutic programs, technology and partnerships.
  • We are part of the revolution in medicine, pioneering therapeutics and technology in cell therapy.
  • Reinforcing the Executive Committee team is crucial for the next phase in our future growth," Frederic Desdouits, PhD, CEO of TreeFrog Therapeutics.
  • For further information on the Executive Committee, visit www.treefrog.fr

TREEFROG THERAPEUTICS REINFORCES EXECUTIVE COMMITTEE WITH THREE NEW MEMBERS

Retrieved on: 
Thursday, November 9, 2023
University of Los Andes (Colombia), IPO, Biogen, Therapy, Tajikistan State University of Law, Business, & Politics, Tree, Doctor of Philosophy, MBA, Engineering, HEC Paris, Central Executive Committee (PAP), Politics, Growth, Trinity College, Medicine, Paris, Executive Committee, Business, Senior, University of Hamburg, Ethicon, University, Trinity College Dublin, Sanofi, International communication, La Jolla Institute for Immunology, Immunology, Management, Bayer, Merck

BORDEAUX, France, Nov. 9, 2023 /PRNewswire/ -- TreeFrog Therapeutics, a global biotechnology company advancing a pipeline of cell therapies based on a disruptive proprietary technology platform, today announced the appointment of three new members to the Executive Team.

Key Points: 
  • "Since our inception in 2018, TreeFrog has made great strides, and I am proud of the progress the teams have made in our therapeutic programs, technology and partnerships.
  • We are part of the revolution in medicine, pioneering therapeutics and technology in cell therapy.
  • Reinforcing the Executive Committee team is crucial for the next phase in our future growth," Frederic Desdouits, PhD, CEO of TreeFrog Therapeutics.
  • For further information on the Executive Committee, visit www.treefrog.fr

Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Retrieved on: 
Tuesday, November 7, 2023
Neurofilament light polypeptide, MPS II, CLE, Biomarker, Therapy, MS, BioRxiv, ETV, Ulcerative colitis, BBB, ALS, PTV, ATV, ROFN, Definitive, Traffic barrier, Hunter syndrome, Phase 10, Denali, MPS, Antibody, Biology, Safety, Patient, AFL, Plaque, Fluid mechanics, ASO, ARIA, RIPK1, Asos, Research, Cerebrospinal fluid, ISR, SGSH, DSM-IV codes, Nerve, Brain, Society, Total, OTV, N-sulfoglucosamine sulfohydrolase, Hunting, LUMA, Glycogen storage disease, Manuscript, UC, CSF, Amyloid-related imaging abnormalities, Takeda, COMPASS, Pathology, CNS, Sanfilippo, Neuroinflammation, Collaboration, Multiple sclerosis, Sanfilippo syndrome, IDS, Cognition, Mutation, SAN, Pharmaceutical industry, Medical imaging, Fine chemical, Cryptocurrency, Biogen, LRRK2, Metabolism, Sanofi

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the third quarter ended September 30, 2023, and provided business highlights.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the third quarter ended September 30, 2023, and provided business highlights.
  • Denali has selected five ASO targets for further development and is focused on advancing two OTV candidates towards clinical development.
  • 2023 Guidance on Operating Expenses:
    Cash, cash equivalents, and marketable securities were approximately $1.12 billion as of September 30, 2023.
  • General and administrative expenses were $25.3 million and $23.3 million for the three months ended September 30, 2023 and 2022, respectively.

Sage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress

Retrieved on: 
Tuesday, November 7, 2023
Research, Mental Health, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, Woman, AD, PD, Food, MCI, DSM-IV codes, European Medicines Agency, Deficit spending, CIV, GABAA, Risk, Schedule, Sale, Essential tremor, MDD, HD, Workforce, DEA, Acquisition, Webcast, EMA, Safety, Therapy, Patient, D, PPD, Plasma, Tremor, ODD, Zuranolone, Education, Incidence, PAM, Anxiety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NMDA, Diagnosis, Grammatical mood, Nursing, Pharmaceutical industry, Dietary supplement, Surveying, Elevator mechanic, Biogen, Sage

Sage Therapeutics, Inc. (Nasdaq: SAGE) today reported business highlights and financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Sage Therapeutics, Inc. (Nasdaq: SAGE) today reported business highlights and financial results for the third quarter ended September 30, 2023.
  • ZURZUVAE is being developed and commercialized in collaboration with Biogen Inc. Sage also commercializes ZULRESSO® (brexanolone) CIV injection in the treatment of PPD.
  • Restructuring Expenses: Restructuring expenses were $33.6 million in the third quarter of 2023 due to the August 2023 corporate reorganization.
  • ET to review its third quarter 2023 financial results and discuss recent corporate updates.

Update relating to LEQEMBI® from Eisai's investor presentation of their quarterly report published today

Retrieved on: 
Tuesday, November 7, 2023
AD, Alzheimer's disease, Neurology, Co-promotion, IDN, CET, Patient, EU, Arms industry, Pharmaceutical industry, Biogen, Eisai

BioArctic has the right to high single digit royalty on global sales of LEQEMBI.

Key Points: 
  • BioArctic has the right to high single digit royalty on global sales of LEQEMBI.
  • BioArctic's complete interim report for the third quarter 2023 will be published on November 8 at 08:00 CET.
  • This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation.
  • The information was released for public disclosure, through the agency of the contact persons below, on November 7, 2023, at 09:15 a.m. CET.

Update relating to LEQEMBI® from Eisai's investor presentation of their quarterly report published today

Retrieved on: 
Tuesday, November 7, 2023
AD, Alzheimer's disease, Neurology, Co-promotion, IDN, CET, Patient, EU, Arms industry, Pharmaceutical industry, Biogen, Eisai

BioArctic has the right to high single digit royalty on global sales of LEQEMBI.

Key Points: 
  • BioArctic has the right to high single digit royalty on global sales of LEQEMBI.
  • BioArctic's complete interim report for the third quarter 2023 will be published on November 8 at 08:00 CET.
  • This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation.
  • The information was released for public disclosure, through the agency of the contact persons below, on November 7, 2023, at 09:15 a.m. CET.